Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with endothelin antagonists

D J Webb1, F E Strachan

  • 1Clinical Pharmacology Unit and Research Centre, The University of Edinburgh, Western General Hospital, Scotland.

American Journal of Hypertension
|June 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Squeezing, trisqueezing and quadsqueezing in a hybrid oscillator-spin system.

Nature physics·2026
Same author

Breaking the Entangling Gate Speed Limit for Trapped-Ion Qubits Using a Phase-Stable Standing Wave.

Physical review letters·2023
Same author

Long-period gratings for monitoring the resin transfer molding of fiber-reinforced polymer composites.

Optics letters·2023
Same author

Ultraviolet A radiation and COVID-19 deaths in the USA with replication studies in England and Italy.

The British journal of dermatology·2021
Same author

Predictors of UK healthcare worker burnout during the COVID-19 pandemic.

QJM : monthly journal of the Association of Physicians·2021
Same author

Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland.

QJM : monthly journal of the Association of Physicians·2019
Same journal

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same journal

Opposite Seasonal Variation in Nighttime and Morning Blood Pressure: A Longitudinal Study of Patients with Hypertension.

American journal of hypertension·2026
Same journal

Screening for Postprandial Hypotension: The Importance of Home Blood Pressure Monitoring.

American journal of hypertension·2026
Same journal

Distinct Mediating Roles of Hypertension in Arterial Stiffness Mechanisms Associated with Cardiovascular Disease Risk: A Community-Based Cohort Study.

American journal of hypertension·2026
Same journal

Long-term systolic blood pressure time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.

American journal of hypertension·2026
Same journal

Estimated Pulse Wave Velocity Predicts Outcomes After Acute Ischemic Stroke: A Multinational Cohort Analysis.

American journal of hypertension·2026
See all related articles

Endothelin-1 is a potent vasoconstrictor involved in cardiovascular diseases like hypertension and heart failure. Endothelin receptor antagonists show promise for treating these conditions by lowering blood pressure and improving hemodynamics.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology

Background:

  • Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by vascular endothelial cells.
  • ET-1 contributes to vasoconstriction and may play a role in hypertension, heart failure, and atherogenesis.

Purpose of the Study:

  • To investigate the role of endothelin-1 in cardiovascular regulation.
  • To evaluate the therapeutic potential of endothelin receptor antagonists in cardiovascular diseases.

Main Methods:

  • Studies utilized endothelin receptor antagonists.
  • Clinical trials assessed effects on blood pressure and hemodynamics in hypertensive and heart failure patients.

Main Results:

  • Endothelin-1 is crucial for maintaining vascular tone and blood pressure in humans, primarily via ETA receptors on vascular smooth muscle.

Related Experiment Videos

  • The endothelin receptor antagonist bosentan effectively reduced blood pressure in hypertensive individuals.
  • Bosentan demonstrated sustained, favorable hemodynamic effects in patients with chronic heart failure.

    • Conclusions:

    • Endothelin receptor antagonists are a promising class of agents for cardiovascular disease treatment.
    • These antagonists offer potential benefits including blood pressure reduction, hemodynamic improvement, and possible inhibition of atherogenesis with a good side-effect profile.